Chemotherapeutic options for gastroesophageal junction tumors Journal Article
| Authors: | Ku, G. Y.; Ilson, D. H. |
| Article Title: | Chemotherapeutic options for gastroesophageal junction tumors |
| Abstract: | A doublet of a fluoropyrimidine and a platinum compound remains the reference regimen in palliative chemotherapy for esophagogastric cancers. Newer regimens involve the substitution of infusional 5-fluorouracil (FU) for a shorter infusional schedule or oral 5-FU prodrugs and the replacement of cisplatin with oxaliplatin. Although the addition of epirubicin to the standard 2-drug regimen is part of routine practice, there are no randomized data to support a benefit. In contrast, the docetaxel-based docetaxel/cisplatin/5-FU regimen has been shown to modestly improve survival compared with 5-FU/cisplatin alone but at the expense of significant additional toxicity, which has hindered widespread acceptance of this regimen. Irinotecan-containing regimens have also been evaluated in a few phase III evaluations but are not clearly superior to 5-FU/cisplatin or even infusional 5-FU alone. Nevertheless, their favorable toxicity profile indicates that infusional 5-FU/irinotecan regimens also represent a first-line therapy option. In addition to its primary role in palliative therapy, there are also now established peri- or postoperative chemotherapy strategies that increase survival rates by approximately 10-15% compared with surgery alone. Preoperative chemoradiation in esophageal and gastroesophageal junction tumors has also been shown to improve outcomes. © 2013 Elsevier Inc. |
| Journal Title: | Seminars in Radiation Oncology |
| Volume: | 23 |
| Issue: | 1 |
| ISSN: | 1053-4296 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2013-01-01 |
| Start Page: | 24 |
| End Page: | 30 |
| Language: | English |
| DOI: | 10.1016/j.semradonc.2012.09.003 |
| PROVIDER: | scopus |
| PUBMED: | 23207044 |
| DOI/URL: | |
| Notes: | --- - "Export Date: 1 April 2013" - "CODEN: SRONE" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work